I
IOOF Investment Management Limited
+ Con en carteraSGP
-2.21%
Rentabilidad a 3 meses
$24.000
-0.698 (-2.91%)Al cierre
Loading chart…
- Máximo
- 24.840
- Apertura
- 24.740
- Precio medio ponderado por volumen
- 24.26
- Volumen
- 70.65K
- Capitalización
- —
- Mínimo
- 23.940
- Importe
- 1.71M
- EV/EBITDA, TTM
- 0.00
SpyGlass Pharma Inc is a United States-based ophthalmic drug delivery company. The Company is focused on developing and commercializing long-term, drug delivery solutions for patients suffering from ophthalmic diseases. Its lead product candidate is SpyGlass Drug Delivery Platform with bimatoprost, which is designed to deliver three years of bimotic anti-inflammatory therapy to targeted tissues in the eye.
Análisis de IA of SpyGlass Pharma Inc (SGP)
VenderSpyGlass Pharma, Inc. is not a good buy right now due to its significant net losses and poor technical indicators. The stock is currently priced at $24.00, with a 5-day change of -3.69% and a 20-day change of -17.47%. The RSI is at 39.059, indicating that the stock is nearing oversold territory, but the overall trend remains negative. The company reported a net loss of $19.9 million for Q2 2026, which is a substantial increase from previous losses, highlighting ongoing financial struggles. The main risk is the continued increase in expenses, particularly R&D and administrative costs, which could further impact profitability.
Métricas de valoración
El PER previsto actual de SpyGlass Pharma Inc (SGP) es 0.00, frente a su media de 5 años de .
Ballenas con SGP en cartera
Cronología de eventos
Noticias
9.508-19Yahoo FinanceStockland Reports 10.4% FFO Growth in Latest Earnings
4.508-14Yahoo FinanceCPI and PPI Data Spark Market Rally
9.508-06NASDAQ.COMSpyGlass Pharma Reports Wider Q2 Net Loss Amid Rising Expenses
9.505-15seekingalphaSpyGlass Pharma Reports Q1 Financial Results
- 8.503-26seekingalpha
SpyGlass Pharma Reports Q4 Earnings and IPO Details
Preguntas frecuentes sobre SGP, respondidas por Alphio AI
SpyGlass Pharma Inc is a United States-based ophthalmic drug delivery company. The Company is focused on developing and commercializing long-term, drug delivery solutions for patients suffering from ophthalmic diseases. Its lead product candidate is SpyGlass Drug Delivery Platform with bimatoprost, which is designed to deliver three years of bimotic anti-inflammatory therapy to targeted tissues in the eye. It operates in the Healthcare sector.
SpyGlass Pharma, Inc. is not a good buy right now due to its significant net losses and poor technical indicators. The stock is currently priced at $24.00, with a 5-day change of -3.69% and a 20-day change of -17.47%. The RSI is at 39.059, indicating that the stock is nearing oversold territory, but the overall trend remains negative. The company reported a net loss of $19.9 million for Q2 2026, which is a substantial increase from previous losses, highlighting ongoing financial struggles. The main risk is the continued increase in expenses, particularly R&D and administrative costs, which could further impact profitability.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.